Application-led Design
Align antigen format, epitope intent and downstream use before selection
Phage Display Antibody Discovery
From selection strategy to traceable candidate sequences.
Request NowOverview
Using phage-displayed antibody libraries, PROVETOP combines antigen presentation, positive enrichment, counter-selection and progressive stringency to identify candidates with the intended binding profile.
The project can continue through sequence clustering, monoclonal verification, affinity assessment and goal-specific functional evaluation, creating a traceable basis for antibody engineering and recombinant production.
Selection design begins with the antigen format, desired epitope, cross-reactivity boundary and downstream application rather than a fixed panning recipe.
Highlights
Positive & Counter-selection
Combine target enrichment with removal of known background binders
Sequence-linked Candidates
Connect positive clones to sequence families and representative candidates
Traceable Decisions
Retain round records, screening data and candidate rationale
Antibody Discovery Workflow
- Project AssessmentDefine antigen, epitope intent and application
- Antigen & Library SetupChoose presentation and prepare controls
- Panning, Counter-selection & EnrichmentDeplete background, adjust stringency and review each round
- Monoclonal ScreeningTest, sequence, deduplicate and cluster
- Candidate ConfirmationRetest, rank and compile the data package
Service Details
| Stage | Execution | Project Output |
|---|---|---|
| Project Assessment | Align antigen, desired epitope and application; identify tag, carrier and homologue risks. | Assessment record and selection framework |
| Antigen & Library Setup | Choose solid, solution or cell-based presentation; prepare controls and counter-selection materials. | Presentation plan and experimental design |
| Panning, Counter-selection & Enrichment | Run positive selection and agreed counter-selection; incubate, wash, elute and amplify; adjust stringency and monitor enrichment. | Round records and enrichment trends |
| Monoclonal Screening | Compare monoclonal binding with controls; sequence, deduplicate and cluster families. | Positive clone list and sequence clusters |
| Candidate Confirmation | Retest and rank candidates using the assays agreed for the project. | Candidate shortlist, data package and report |
Project scope, validation methods and schedule are confirmed after review of the target and available antigen material.
Case Studies
Case 1: Monoclonal candidate evidence review
Binding activity
Use concentration-response data to compare target-binding activity before sequence-led candidate selection.
Affinity assessment
Use BLI or SPR sensorgrams to review candidate interaction kinetics when included in the project scope.
Candidate quality
Review electrophoretic purity alongside binding evidence before advancing a recombinant candidate.
Case 2: Candidate affinity confirmation
Activity shortlist
Use target-binding activity to identify candidates suitable for quantitative interaction analysis.
Kinetic ranking
Compare association and dissociation behavior with BLI or SPR under the agreed assay format.
Homogeneity check
Review analytical SEC-HPLC to separate interaction quality from aggregation-related artifacts.
Case 3: Recombinant antibody quality review
Identity and purity
Confirm the expected antibody bands and electrophoretic purity after recombinant production.
Homogeneity
Use SEC-HPLC to review the main peak and aggregation state of the recombinant candidate.
Activity retention
Pair analytical quality results with target-binding activity before downstream evaluation.
Talk with an Antibody Discovery Specialist
Share the target, intended application and available antigen material. The technical team will identify the most useful project starting point.
Technical consultation400-829-0116
Frequently Asked Questions
1. What is phage display antibody selection?
Antibody phenotype and encoding sequence are linked on the same phage particle, enabling iterative binding, washing, elution and amplification.
2. How many rounds are typically required?
Multiple rounds are common, but enrichment, background signal and clone diversity determine whether the strategy continues or changes.
3. Which antigen formats can be used?
Purified proteins, domains, peptides, cells or other agreed formats may be used depending on conformational and validation needs.
4. How is nonspecific binding reduced?
Blocking, pre-adsorption, counter-selection, competitive elution and progressively stringent washing can be combined with appropriate controls.
5. Can candidates continue to expression and validation?
Yes. Candidate sequences can proceed to recombinant production, affinity, competition, cross-reactivity and goal-specific functional assays.
Quotation and Ordering
Begin with the target, intended application and available material. Screening and validation details are confirmed after technical review.
Share the target, antigen format and intended application
Review presentation, background risks and selection goals
Confirm the selection framework, outputs and quotation
Run panning with evidence retained at each round
Review candidates, sequences and agreed validation data
Request a Quote
Emailorder@provetop.com
Phone400-829-0116
Online FormAntibody discovery inquiry
LocationSuzhou Industrial Park